Alcohol consumption and non-Hodgkin lymphoma survival

Journal of Cancer Survivorship

Volumn 4, Issue 2, 2010, Pages 101-109

  Han, Xuesong ^a   Zheng, Tongzhang ^a   Foss, Francine M ^b   Ma, Shuangge ^a   Holford, Theodore R ^a   Boyle, Peter ^c   Leaderer, Brian ^a   Zhao, Ping ^d   Dai, Min ^d   Zhang, Yawei ^a  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

^d PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Alcohol; Liquor; Non Hodgkin lymphoma; Prognosis; Survival; Wine

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; DRINKING BEHAVIOR; FEMALE; FOLLOW UP; HUMAN; MIDDLE AGED; MORTALITY; NONHODGKIN LYMPHOMA; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; UNITED STATES; EPIDEMIOLOGY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALCOHOL DRINKING; CONNECTICUT; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 77953535564     PISSN: 19322259     EISSN: 19322267     Source Type: Journal    
DOI: 10.1007/s11764-009-0111-4     Document Type: Article

References (47)

1. Kloner RA, Rezkalla SH. To drink or not to drink? That is the question. Circulation. 2007; 116: 1306-17.
2. Ginter E, Simko V. Ethanol and cardiovascular diseases: epidemiological, biochemical and clinical aspects. Bratisl Lek Listy. 2008; 109: 590-4.
3. Djousse L, Gaziano JM. Alcohol consumption and heart failure: a systematic review. Curr Atheroscler Rep. 2008; 10: 117-20.
4. McCullough MJ, Farah CS. The role of alcohol in oral carcinogenesis with particular reference to alcohol-containing mouthwashes. Aust Dent J. 2008; 53: 302-5.
5. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol. 2007; 17: 2-9.
6. Marrero JA. Hepatocellular carcinoma. Curr Opin Gastroenterol. 2006; 22: 248-53.
7. Secretan B, Straif K, Baan R, Grosse Y, El Ghissassi F, Bouvard V, et al. A review of human carcinogens-Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol. 2009; 10: 1033-4.
8. Morton LM, Zheng T, Holford TR, Holly EA, Chiu BC, Costantini AS, et al. Alcohol consumption and risk of non-Hodgkin lymphoma: a pooled analysis. Lancet Oncol. 2005; 6: 469-76.
9. Allen NE, Beral V, Casabonne D, Kan SW, Reeves GK, Brown A, et al. Moderate alcohol intake and cancer incidence in women. J Natl Cancer Inst. 2009; 101: 296-305.
10. Chiu BC, Cerhan JR, Gapstur SM, Sellers TA, Zheng W, Lutz CT, et al. Alcohol consumption and non-Hodgkin lymphoma in a cohort of older women. Br J Cancer. 1999; 80: 1476-82.
11. Klatsky AL, Li Y, Baer D, Armstrong MA, Udaltsova N, Friedman GD. Alcohol consumption and risk of hematologic malignancies. Ann Epidemiol 2009.
12. Lim U, Morton LM, Subar AF, Baris D, Stolzenberg-Solomon R, Leitzmann M, et al. Alcohol, smoking, and body size in relation to incident Hodgkin's and non-Hodgkin's lymphoma risk. Am J Epidemiol. 2007; 166: 697-708.
13. Diaz LE, Montero A, Gonzalez-Gross M, Vallejo AI, Romeo J, Marcos A. Influence of alcohol consumption on immunological status: a review. Eur J Clin Nutr. 2002; 56 Suppl 3: S50-3.
14. Poschl G, Seitz HK. Alcohol and cancer. Alcohol and alcoholism. 2004; 39: 155-65.
15. Battaglioli T, Gorini G, Costantini AS, Crosignani P, Miligi L, Nanni O, et al. Cigarette smoking and alcohol consumption as determinants of survival in non-Hodgkin's lymphoma: a population-based study. Ann Oncol. 2006; 17: 1283-9.
16. Talamini R, Polesel J, Spina M, Chimienti E, Serraino D, Zucchetto A, et al. The impact of tobacco smoking and alcohol drinking on survival of patients with non-Hodgkin lymphoma. Int J Cancer. 2008; 122: 1624-9.
17. Zhang Y, Holford TR, Leaderer B, Boyle P, Zahm SH, Flynn S, et al. Hair-coloring product use and risk of non-Hodgkin's lymphoma: a population-based case-control study in Connecticut. Am J Epidemiol. 2004; 159: 148-54.
18. Morton LM, Holford TR, Leaderer B, Zhang Y, Zahm SH, Boyle P, et al. Alcohol use and risk of non-Hodgkin's lymphoma among Connecticut women (United States). Cancer Causes Control. 2003; 14: 687-94.
19. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909-18.
20. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999; 17: 3835-49.
21. Ghali WA, Quan H, Brant R, van Melle G, Norris CM, Faris PD, et al. Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. Jama. 2001; 286: 1494-7.
22. Nieto FJ, Coresh J. Adjusting survival curves for confounders: a review and a new method. Am J Epidemiol. 1996; 143: 1059-68.
23. He S, Sun C, Pan Y. Red wine polyphenols for cancer prevention. Int J Mol Sci. 2008; 9: 842-53.
24. Fernandez-Panchon MS, Villano D, Troncoso AM, Garcia-Parrilla MC. Antioxidant activity of phenolic compounds: from in vitro results to in vivo evidence. Crit Rev Food Sci Nutr. 2008; 48: 649-71.
25. Udenigwe CC, Ramprasath VR, Aluko RE, Jones PJ. Potential of resveratrol in anticancer and anti-inflammatory therapy. Nutr Rev. 2008; 66: 445-54.
26. de la Lastra CA, Villegas I. Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol Nutr Food Res. 2005; 49: 405-30.
27. Delmas D, Lancon A, Colin D, Jannin B, Latruffe N. Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Curr Drug Targets. 2006; 7: 423-42.
28. Benitez DA, Pozo-Guisado E, Alvarez-Barrientos A, Fernandez-Salguero PM, Castellon EA. Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J Androl. 2007; 28: 282-93.
29. Bishayee A, Dhir N. Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. Chem Biol Interact. 2009; 179: 131-44.
30. Kuo PL, Hsu YL. The grape and wine constituent piceatannol inhibits proliferation of human bladder cancer cells via blocking cell cycle progression and inducing Fas/membrane bound Fas ligand-mediated apoptotic pathway. Mol Nutr Food Res. 2008; 52: 408-18.
31. Leifert WR, Abeywardena MY. Grape seed and red wine polyphenol extracts inhibit cellular cholesterol uptake, cell proliferation, and 5-lipoxygenase activity. Nutr Res. 2008; 28: 842-50.
32. Lee KW, Kang NJ, Heo YS, Rogozin EA, Pugliese A, Hwang MK, et al. Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Res. 2008; 68: 946-55.
33. Lee KW, Kang NJ, Rogozin EA, Kim HG, Cho YY, Bode AM, et al. Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1. Carcinogenesis. 2007; 28: 1918-27.
34. Shimizu T, Nakazato T, Xian MJ, Sagawa M, Ikeda Y, Kizaki M. Resveratrol induces apoptosis of human malignant B cells by activation of caspase-3 and p38 MAP kinase pathways. Biochem Pharmacol. 2006; 71: 742-50.
35. King RE, Kent KD, Bomser JA. Resveratrol reduces oxidation and proliferation of human retinal pigment epithelial cells via extracellular signal-regulated kinase inhibition. Chem Biol Interact. 2005; 151: 143-9.
36. D'Archivio M, Santangelo C, Scazzocchio B, Vari R, Filesi C, Masella R, et al. Modulatory effects of polyphenols on apoptosis induction: relevance for cancer prevention. Int J Mol Sci. 2008; 9: 213-28.
37. Juan ME, Wenzel U, Daniel H, Planas JM. Resveratrol induces apoptosis through ROS-dependent mitochondria pathway in HT-29 human colorectal carcinoma cells. J Agric Food Chem. 2008; 56: 4813-8.
38. Larrosa M, Tomas-Barberan FA, Espin JC. The grape and wine polyphenol piceatannol is a potent inducer of apoptosis in human SK-Mel-28 melanoma cells. Eur J Nutr. 2004; 43: 275-84.
39. Hertog MG, Kromhout D, Aravanis C, Blackburn H, Buzina R, Fidanza F, et al. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch Intern Med. 1995; 155: 381-6.
40. Knekt P, Jarvinen R, Reunanen A, Maatela J. Flavonoid intake and coronary mortality in Finland: a cohort study. BMJ. 1996; 312: 478-81.
41. Hirvonen T, Pietinen P, Virtanen M, Ovaskainen ML, Hakkinen S, Albanes D, et al. Intake of flavonols and flavones and risk of coronary heart disease in male smokers. Epidemiology. 2001; 12: 62-7.
42. Yochum L, Kushi LH, Meyer K, Folsom AR. Dietary flavonoid intake and risk of cardiovascular disease in postmenopausal women. Am J Epidemiol. 1999; 149: 943-9.
43. Rotondo S, Di Castelnuovo A, de Gaetano G. The relationship between wine consumption and cardiovascular risk: from epidemiological evidence to biological plausibility. Ital Heart J. 2001; 2: 1-8.
44. Streppel MT, Ocke MC, Boshuizen HC, Kok FJ, Kromhout D. Long-term wine consumption is related to cardiovascular mortality and life expectancy independently of moderate alcohol intake: the Zutphen Study. J Epidemiol Community Health 2009.
45. Athyros VG, Liberopoulos EN, Mikhailidis DP, Papageorgiou AA, Ganotakis ES, Tziomalos K, et al. Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, coronary heart disease, stroke, and peripheral arterial disease in a Mediterranean cohort. Angiology. 2007; 58: 689-97.
46. Demark-Wahnefried W, Rock CL, Patrick K, Byers T. Lifestyle interventions to reduce cancer risk and improve outcomes. Am Fam Physician. 2008; 77: 1573-8.
47. Surveillance, Epidemiology, and End Results (SEER) Program (www. seer. cancer. gov) SEER*Stat Database: Incidence-SEER 17 Regs Limited-Use + Hurricane Katrina Impacted Louisiana Cases, Nov 2007 Sub (1973-2005 varying)-Linked To County Attributes-Total U. S., 1969-2005 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008, based on the November 2007 submission.